Furthermore, NF-κB inhibition by administration of Withaferin A, a known NF-κB inhibitor, reduced ALS disease symptoms in a TDP-43 transgenic mouse model [14] and extended lifespan of mutant SOD1 ALS mice [15]. This evidence concerns the gene NFKB1 and amyotrophic lateral sclerosis.